{
    "nct_id": "NCT03897543",
    "official_title": "A Phase 1-2 Study of ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma",
    "inclusion_criteria": "* Men or women, Age â‰¥18 years\n* Patients with ECOG performance status 0 or 1\n* Patients with histologically confirmed diagnosis of HCC not amenable to curative surgery or local therapy\n* Patients with documented objective radiographic progression during or after local therapy or after treatment with sorafenib or lenvatinib or intolerance to or refusal to receive either agent\n* Patients with at least one prior systemic therapy for HCC\n* Patients eligible to be treated with nivolumab\n* Patients with measurable disease based on RECIST v1.1\n* Patients with Child-Pugh class A liver score within 7 days of first study dose\n* Patients with no history of hepatic encephalopathy\n* Patients with no prior or current clinically significant ascites as measured by physical examination and that requires active paracentesis for control (patients with ascites only on radiographic imaging are eligible)\n* Patients with HBV infection must have received antiviral therapy for at least 12 weeks and HBV viral load must be documented to be <100 IU/mL within 7 days of first study dose\n* Patients with no active co-infection with HBV and HCV or HBV and HDV\n* Patients with no active drug or alcohol abuse\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with tyrosine kinase inhibitor treatment within 2 weeks of first study dose\n* Patients with esophageal or gastric variceal bleeding within the past 6 months\n* Patients with portal vein invasion at the main portal (Vp4) or the inferior vena cava or cardiac involvement of HCC based on imaging\n* Patients with previous solid organ or hematologic transplantation\n* Patients with active autoimmune disease requiring systemic treatment in the past 2 years\n* Patients with diagnosis of immunodeficiency or receiving systemic steroid therapy or other immunosuppressive therapy within 7 days before first study dose\n* Patients with previous locoregional therapy or major surgery to the liver within 6 weeks before first study dose\n* Patients with minor surgery to liver or another site within 1 week before first study dose",
    "miscellaneous_criteria": ""
}